Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Open Access
- 23 April 2021
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (18) , 4974-4982
Abstract
Chromosomal rearrangements of NTRK1–3 resulting in gene fusions (NTRK gene fusions) have been clinically validated as oncogenic drivers in a wide range of human cancers. Typically, NTRK gene fusions involve both inter- and intrachromosomal fusions of the 5′ regions of a variety of genes with the 3′ regions of NTRK genes leading to TRK fusion proteins with constitutive, ligand-independent activation of the intrinsic tyrosine kinase. The incidence of NTRK gene fusions can range from the majority of cases in certain rare cancers to lower rates in a wide range of more common cancers. Two small-molecule TRK inhibitors have recently received regulatory approval for the treatment of patients with solid tumors harboring NTRK gene fusions, including the selective TRK inhibitor larotrectinib and the TRK/ROS1/ALK multikinase inhibitor entrectinib. In this review, we consider the practicalities of detecting tumors harboring NTRK gene fusions, the pharmacologic properties of TRK inhibitors currently in clinical development, the clinical evidence for larotrectinib and entrectinib efficacy, and possible resistance mechanisms.Keywords
Funding Information
- Jim Heighway of Cancer Communications and Consultancy
- Bayer
- Justyna Wierzbinska
This publication has 55 references indexed in Scilit:
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Cancer Discovery, 2015
- Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinomaCancer Letters, 2015
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsNature Medicine, 2015
- circlizeimplements and enhances circular visualization in RBioinformatics, 2014
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAClinical Cancer Research, 2014
- Kinase fusions are frequent in Spitz tumours and spitzoid melanomasNature Communications, 2014
- Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor EntityAmerican Journal of Surgical Pathology, 2010
- Administration of a Tropomyosin Receptor Kinase Inhibitor Attenuates Sarcoma-Induced Nerve Sprouting, Neuroma Formation and Bone Cancer PainMolecular Pain, 2010
- Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lungHuman Mutation, 2008
- Neurotrophins: Roles in Neuronal Development and FunctionAnnual Review of Neuroscience, 2001